2Lenz HJ,Van Cutsem E,Khambata-Ford S,et al.Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan,oxaliplatin,and fluoropyrimidines[J].J Clin Oncol,2006,24:4914-4921.
3Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351:337-345.
4Wacker B,Nagrani T,Weinberg J,et al.Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies[J].Clin Cancer Res,2007,13:3913-3921.
5Ciardiello F,Tortora G.EGFR antagonist in cancer treatment[J].N Engl J Med,2008,358:1160-1174.
6Bezjak A,Tu D,Seymour L,et al.Symptom improvement in lung cancer patients treated with erlotinib:Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study[J].J Clin Oncol,2006,24:3831-3837.
3NCI. Cancer therapy evaluation program,common terminology cri- teria for adverse events version 3.0[EB/OL]. [2011 -09 -23]. ht- tp//ctep, cancer, gov.
4Min,JH. Lee, HY. Lim, H. et al. Ahn KPark, MP. Chung. Drug - induced interstitial disease in tyrosine kinase inhibitor therapy for non -small cell lung cancer: A review on current insight[J]. Cancer Chemother Pharmacol, 2011,68: 1099 - 1109.
5National Cancer Institute. Cancer Therapy Evaluation Pro- gram,Common Terminology Criteria for Adverse Events Ver- sion 3.0 [DB/OL].(2006-08-09 )[2013-03-01].http://ctep cancer.gov/protocolDevelopment/electronic_applications/ctc. htm#ctc_40.
